# Study of Pembrolizumab in the First Line Therapy for R/M HNSCC in China

> **NCT04740996** · — · UNKNOWN · sponsor: **Shi Yuankai** · enrollment: 30 (estimated)

## Conditions studied

- Head and Neck Squamous Cell Carcinoma

## Interventions

- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT04740996
- **Lead sponsor:** Shi Yuankai
- **Sponsor class:** UNKNOWN
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-02-04
- **Primary completion:** 2024-02
- **Final completion:** 2024-02
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2022-02-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04740996

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04740996, "Study of Pembrolizumab in the First Line Therapy for R/M HNSCC in China". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04740996. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*